Centiva Capital, LP Intellia Therapeutics, Inc. Transaction History

Centiva Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $199,665 - $265,505	3,703 New	3,703 $207,000
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $106,232 - $210,339	-2,760 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $160,825 - $328,412	2,760 New	2,760 $201,000
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $373,618 - $513,038	-3,708 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $490,827 - $655,500	3,708 New	3,708 $497,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $867M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.